Business
Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
Company to Present New APVO436 Expansion Phase Trial Data at Upcoming American Society of Hematology Annual Meeting and ExpositionSEATTLE, WA / ACCESSWIRE /
About this update from Aptevo Therapeutics Inc.
[{"type":"text","content":"Company to Present New APVO436 Expansion Phase Trial Data at Upcoming American Society of Hematology Annual Meeting and ExpositionSEATTLE, WA / ACCESSWIRE / November 10, 2022 / Aptevo Therapeutics Inc. (\"Aptevo\" or the \"Company\") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results and business highlights for the quarter ended September 30, 2022.Business HighlightsPresenting new Phase 1b expansion trial data for APVO436 in the treatment of Acute Myeloid Leukemia (AML) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13 in New Orleans, LouisianaThe poster, entitled \"Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 ADAPTIR™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome\" will be presented on Sunday, December 11, 2022 from 6:00 PM-8:00 PM Central timeAnnounced that the US Food and Drug Administration (FDA) issued a \"may proceed\" notification for the ALG.APV-527 investigational new drug application (IND), allowing the initiation of clinical trials evaluating the compound for the treatment of 5T4-expressing tumors in multiple solid tumor typesContinued dosing patients in the Company's Phase 1b expansion program evaluating APVO436 for the treatment of acute myeloid leukemia in both combination therapy and monotherapy\"We are very excited to present our APVO436 expansion phase data at the upcoming ASH meeting, fulfilling a promise we made earlier in the year and further underscoring our enthusiasm for the compound and rationale for its continued advancement in the clinic. We are also working to rapidly progress ALG.APV-527 in the clinic for evaluation in the treatment of solid tumors. Advancing our work across these programs will put us in a strong position to produce meaningful data readouts across our clinical programs in 2023,\" said Marvin White, President and CEO of Aptevo. Mr. White added \"The combination of our existing cash and future expected milestone payments provides us sufficient runway to conduct our business for at least the next twelve months.\"Third Quarter 2022 Financial Results SummaryCash Position: Aptevo had cash...